Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis

A nonavalent human papillomavirus (HPV) vaccine has been licensed for use in women and men up to age 45 years in the United States. The cost-effectiveness of HPV vaccination for women and men aged 30 to 45 years in the context of cervical cancer screening practice was evaluated to inform national gu...

Full description

Saved in:
Bibliographic Details
Published in:PLoS medicine 2021-03, Vol.18 (3), p.e1003534
Main Authors: Kim, Jane J., Simms, Kate T., Killen, James, Smith, Megan A., Burger, Emily A., Sy, Stephen, Regan, Catherine, Canfell, Karen
Format: Article
Language:English
Subjects:
Adults
Age
Analysis
Biology and Life Sciences
Calibration
Cervical cancer
Cervix
Complications and side effects
Cost analysis
Decision making
Disease
Disease transmission
Females
Genotypes
Health aspects
Human papillomavirus
Immunotherapy
Infections
Medical care, Cost of
Medical screening
Medicine and Health Sciences
Mortality
Multiple births
Natural history
Papillomavirus infections
Penis
Population
Prevention
Risk factors
Social Sciences
Surveillance
Teenagers
Vaccines
Vagina
Warts
Womens health
Young adults
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!